Clinical trials
Phase 2 Prostatic Neoplasms trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Terminated | 5 |
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Unknown status | 3 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radboud University Medical Center | 4 |
| Astellas Pharma Inc | 2 |
| AstraZeneca | 2 |
| Erasmus Medical Center | 2 |
| Ferring Pharmaceuticals | 2 |
| Ipsen | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| Bayer | 1 |
| Bristol-Myers Squibb | 1 |
| Centocor, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 35 |
| Esophageal Neoplasms | 2 |
| Neoplastic Cells, Circulating | 2 |
| Ovarian Neoplasms | 2 |
| Prostatic Neoplasms, Castration-Resistant | 2 |
| Adenocarcinoma | 1 |
| Brain Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Bulbo-Spinal Atrophy, X-Linked | 1 |
| Carcinoma | 1 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.